Kangtai Bio | Briefing, News, Analysis, Research, Data

Kangtai Bio

Kangtai Bio a famous international pharmaceutical company

Kangtai Bio is one of the first high-tech enterprises in Shenzhen, mainly engaged in the development, production and sales of biological products. It has a team of vaccine industry professionals who have made important breakthroughs in the research and development of new vaccines. The production line is imported from Merck, a famous international pharmaceutical company, and its safety and efficacy have been guaranteed, and the products have covered 31 provinces, municipalities and autonomous regions.

Sector

Healthcare

Industry

Biotech/Pharma

Sub-industry

Founded

Sept 8, 1992

HQ location

Guangdong, China

Legal name

Shenzhen Kangtai Biological Products Co., Ltd.

Website

http://www.biokangtai.com/

office@biokangtai.com

Employees

501-1000

All
News
Analysis
Research

Briefing Yesterday 06:44 PM · Technology | Healthcare

Zhongxin fluoromaterials: it is planned to acquire 51% equity of Jiangxi Exxon through equity transfer and cash capital increase

Briefing Jun 24, 2022 11:15 AM · Healthcare

F-star to be acquired by China biopharmaceutical with USD 161million

In-depth

Healthcare

Exclusive Interview with Xu Qian, Managing Partner of Redhill Capital

The investors have a partiality for the projects which could meet clinical needs, possess cutting-edge innovation technology and a talented team.

Yesterday 12:24 PM

Briefing Jun 24, 2022 11:07 AM · Healthcare

"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange

Briefing Jun 24, 2022 10:59 AM · Technology | Healthcare

Herui gene launched the early screening product "quansining" for multiple cancer types, covering six high-risk cancer types

Research

Healthcare, Technology, Financials

WIA2020 | 30 Tech Entrepreneurs in China

Apr 22, 2021 03:11 PM

Research

Healthcare, Technology, Consumer Staples

WIA2020 | Rising Tech Stars 2020: Global & China's 100

Dec 09, 2020 09:57 AM

Research

Healthcare

WIA2020 | Next 50 in Global Tech: Healthcare

Dec 09, 2020 09:39 AM

Research

Real Estate, Consumer Discretionary, Industrials

Tech for Global, Globalization Footprints of the Established and the New

May 29, 2020 08:30 PM

Briefing Jun 24, 2022 10:46 AM · Healthcare

East China medicine "liraglutide" goes to sea

Briefing Jun 23, 2022 06:25 PM · Healthcare

Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care

Briefing Jan 28, 2022 07:49 PM · Technology | Healthcare

Kangtai biology: the net profit in 2021 is expected to increase by 76.68% - 106.13% year-on-year

Briefing Jan 23, 2022 05:59 PM · Healthcare

Kangtai biology: CDE starts the on-site verification of the registration of freeze-dried human rabies vaccine (human diploid cells)

In-depth

Healthcare

BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious

BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.

Jun 24, 2022 12:13 PM

Healthcare

Bio-based Materials Manufacturer Mojia Bio Nets USD 80 Mn in Series B Round

For synthetic biology companies, the bottlenecks are controlling the cost and achieving industrialization.

Jun 23, 2022 10:20 PM

Briefing Sep 17, 2021 02:24 PM · Technology | Consumer Staples

Before the festival, the market of "drinking and taking medicine" reappeared, and the food and beverage ETF (515170) rose 2.5%

Briefing Sep 17, 2021 12:03 PM · Technology | Healthcare

2021 China Internet development innovation and investment competition (Changsha) public welfare project and Beidou Innovation Application Challenge kicked off

Briefing Sep 05, 2021 05:52 PM · Financials | Healthcare

Anxin strategy: high prosperity configuration and low position trading

Healthcare

RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round

Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.

Jun 23, 2022 03:45 PM

Technology, Healthcare

Noah Hospital Logistics Robot Received over Ten Million CNY in Series B+ Round

Noah Hospital Logistics Robot recently received over ten million CNY in Series B+ round, with most of the funds going toward product development and marketing.

Jun 22, 2022 06:21 PM

Briefing Aug 06, 2021 01:08 PM · Financials | Technology | Healthcare

Will Huawei's server business be packaged for sale? Huawei insiders: business is affected but will not give up

Briefing Jul 23, 2021 10:13 AM · Healthcare

Pharmaceutical and biological stocks fell sharply in early trading

Briefing Jul 19, 2021 05:45 PM · Healthcare | Financials | Automotive

Samsung Xincai replied to the regulatory letter: there is no direct or indirect misappropriation of raised funds through entrusted loans

Briefing May 26, 2021 10:06 AM · Financials | Healthcare

Vaccine stocks weakened in early trading

EqualOcean Analysis

EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.

Address

Beijing 9 Xiaguangli, 10F Block A CEC Development Mansion, Chaoyang Dc, Beijing 100125, China
Shanghai 2707-2708, AI Tower, 701 Yunjin Road, Xuhui Dc, Shanghai 200232, China

New York Suite 2967, 29th Floor, 4 World Trade 150 Greenwich St, New York, NY 10006

About